
Discover an innovative approach to enhance PARP inhibitor effectiveness in BRCA1/2 wild-type cancers. Depleting p53R2, reducing HR factor CtIP, and inhibiting CK2 phosphorylation synergize with PARP inhibition, rendering these cancers more susceptible. This strategy offers a promising synthetic lethal combination for improved therapeutic outcomes.
Like
Save
Share